Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, is in Phase 2 development in chronic pain patients. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

 Key Statistics

Ownership: Public

Web Site: Nektar Therapeutics (CA)
Employees: 421
Symbol: NKTR

 Company News
Nektar Therapeutics (CA) (NKTR) Stock Trading Halted Today; FDA Advisory Committee To Discuss Peripherally-Acting Opioid Receptor Antagonists 6/11/2014 9:42:15 AM
Nektar Therapeutics (CA) (NKTR) Presents Positive Preclinical Data For NKTR-214, A Novel Cancer Immunotherapy, At 50th American Society of Clinical Oncology Meeting 6/2/2014 6:46:36 AM
Nektar Therapeutics (CA) (NKTR) Appoints Ivan Gergel, M.D. As Senior Vice President, Drug Development & Chief Medical Officer 5/19/2014 6:35:38 AM
Nektar Therapeutics (CA) (NKTR) To Present At The UBS 2014 Global Healthcare Conference In New York City 5/19/2014 6:16:34 AM
Nektar Therapeutics (CA) (NKTR) Reports Financial Results For The First Quarter Of 2014 5/8/2014 6:40:15 AM
Nektar Therapeutics (CA) (NKTR) To Announce Financial Results For The First Quarter 2014 On Wednesday, May 7, 2014, After Close Of U.S.-Based Financial Markets 5/2/2014 8:53:54 AM
Nektar Therapeutics (CA) (NKTR) Reports Positive Preclinical Data For Two Oncology Programs At 2014 American Association for Cancer Research 4/9/2014 8:06:43 AM
Nektar Therapeutics (CA) (NKTR) Reports Fourth Quarter And Year-End 2013 Financial Results 2/27/2014 6:30:05 AM
Nektar Therapeutics (CA) (NKTR) To Announce Financial Results For The Fourth Quarter And Year-End Of 2013 On Wednesday, February 26, 2014, After Close Of U.S.-Based Financial Markets 2/20/2014 6:20:21 AM
Nektar Therapeutics (CA) (NKTR) Prices Public Offering Of Common Stock 1/23/2014 11:07:05 AM